Amgen gets FDA approval for its inflammatory diseases treatment Wezlana

Amgen AMGN has received approval from the U.S. Food and Drug Administration for Wezlana, its treatment for multiple inflammatory diseases.

Wezlana was approved as a biosimilar to and interchangeable with Stelara for treating adults with moderate to severe plaque psoriasis, active psoriatic arthritis, moderately to severely active Crohn’s disease and moderate to severely active ulcerative colitis.

The…